Telehealth moves ahead of the evidence
Telehealth companies are starting to offer GLP-1 drugs off-label for addiction, moving ahead of clinical trials and potential new approvals. Over the past year, several platforms specializing in addiction treatment have marketed branded and compounded GLP-1 prescriptions for alcohol use disorder and other addictions.
That puts prescribing ahead of a still-developing evidence base. Off-label use means a clinician prescribes a drug for a purpose that hasn’t been established through a specific approval for that condition. It doesn’t, by itself, show that the treatment works for addiction, and it shouldn’t be confused with the clinical testing now under way.
GLP-1 drugs are associated with treatment for metabolic conditions, while addiction involves patterns of behavior and brain processes that differ from those conditions. Researchers are investigating whether acting on GLP-1 receptors could affect substance use, but a plausible biological explanation isn’t the same as demonstrated clinical benefit. The question is whether the treatment can reduce harmful use in a consistent, measurable way, and whether patients can stay on it safely.
Compounded prescriptions add another layer to the picture. Compounded drugs are prepared for individual patients rather than sold as the same finished product as a branded medicine. Their presence in telehealth marketing means patients may encounter different versions of a drug while the addiction-specific evidence is still being assembled.
A clinical pipeline, with distinct candidates
The clinical pipeline is also taking shape. Eli Lilly is testing brenipatide for alcohol use disorder, Baseline Therapeutics is studying a GLP-1 receptor agonist for alcohol, cocaine, and methamphetamine use disorders, and Altimmune is evaluating pemvidutide for alcohol use disorder. These are separate programs, and the source provides no results showing that any candidate has proved effective.
The breadth of substances being studied matters. Alcohol, cocaine, and methamphetamine use disorders present different treatment challenges; evidence for one condition wouldn’t automatically establish that a drug works for another. A study’s design and results will need to show what happened to the specific group of patients it enrolled, rather than support a broad claim about addiction as a whole.
Clinical studies also do more than ask whether a drug appears promising. They can assess how outcomes are measured, what side effects occur, and whether benefits persist over time. For addiction treatment, a change in use patterns may be important, but interpreting that change requires a clear comparison and careful follow-up.
There’s a difference between a testable theory and a treatment standard.
The gap between access and proof
Telehealth providers are acting before the evidence and approvals catch up. That can create access to a treatment option while formal studies are in progress, but it also puts weight on the quality of the clinical conversation: patients need to understand that the use is off-label and that research is ongoing. Marketing can make a hypothesis sound settled before the data do.
Here's the thing: demand is not evidence. Interest in GLP-1 drugs for addiction may reflect hope for additional treatment choices, but it can’t establish whether patients benefit or whether the approach belongs in routine care. If you're working in this space, the distinction between a prescription being available and a therapy being validated should remain explicit.
That distinction is especially relevant when a telehealth platform combines prescribing with its own public-facing claims. Patients may reasonably infer that a marketed treatment has been tested for the condition named in an advertisement. Yet the source describes ongoing studies and off-label prescribing, not completed trials proving benefit for addiction.
What could change next
Addiction specialists hope the FDA could approve a new medication for alcohol use disorder soon, which would be the first such approval in two decades. That hope points to a wider need for treatment options, but it doesn’t establish that a GLP-1 drug will receive approval or that any current candidate will succeed.
The next meaningful signal will come from the studies now under way. Their findings could clarify whether these medicines help with alcohol use disorder or other substance use disorders, and which patients might benefit. Until then, early prescribing and clinical research will continue on parallel tracks.
This is more significant than it looks: the central issue isn’t simply whether patients can obtain a prescription, but whether the claims made around it can keep pace with evidence. And yet, if the studies show a clear benefit, today’s early interest could help establish demand for a new approach to addiction care. For now, the answer remains open.